Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J. Hsieh, Robert J. Motzer, Umesh Bhanot et al.|European Urology|2016Cited by 204
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 TrialMartin H. Voss, Robert J. Motzer, Albert Reising et al.|Clinical Cancer Research|2018Cited by 38
Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in <i>PBRM1</i> and <i>BAP1</i> with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.Martin H. Voss, A. Ari Hakimi, Fengshen Kuo et al.|Journal of Clinical Oncology|2017Cited by 28
Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.James J. Hsieh, Robert J. Motzer, David Chen et al.|Journal of Clinical Oncology|2015Cited by 26
Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative ReviewWilliam R. Short, Bryn Jones, Parul Patel et al.|Infectious Diseases and Therapy|2024Cited by 5